Intravenous basic fibroblast growth factor produces a persistent reduction in infarct volume following permanent focal ischemia in rats.
Basic fibroblast growth factor (bFGF) is a polypeptide with potent survival-promoting and protective effects on brain cells. In previous studies, we showed that intravenous administration of bFGF reduced infarct volume in models of focal cerebral ischemia in rats, mice, and cats. In these previous studies, infarct volume was measured within 1-7days of the onset of ischemia. The current study was undertaken to determine whether the reduction in infarct volume by bFGF was persistent beyond the first week after stroke. Mature male Sprague-Dawley rats received an intravenous infusion of bFGF (50 microg/kg per h) or vehicle during 0.5-3.5h after permanent proximal middle cerebral artery occlusion. We found a 27% reduction in infarct volume in bFGF- compared to vehicle-treated animals at three months after infarction (P<0.05). The data show that intravenous bFGF treatment produces a persistent reduction in infarct volume, at least up to three months following focal stroke.
Sugimori
H
H
CNS Growth Factor Research Laboratory, Warren 408, Massachusetts General Hospital, Boston, MA 02114, USA.
Speller
H
H
Finklestein
S P
SP
D000818:Animals; D002545:Brain Ischemia / Q000150:complications / Q000473:pathology*; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D020768:Middle Cerebral Artery / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology
D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2